TRAstonDrs

@castltrastondrs.bsky.social

7 months ago

and chimeric antigen receptor T-cell ( #CARTcell ) therapy, are at an increased risk of prolonged #viralshedding, #viralrebound, and persisting infection. This subgroup represents a major clinical challenge,